PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Zacks Investment Research8/24/2026Positive
PRPO
Precipio IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$49.05M
P/E Ratio
—
EPS
$-0.62
Beta
1.33
52W High
$33.63
52W Low
$16.00
50-Day MA
$25.03
200-Day MA
$25.12
Dividend Yield
—
Profit Margin
-4.47%
Forward P/E
15.43
PEG Ratio
0.00
About Precipio Inc
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | $27.20M |
| Gross Profit (TTM) | $12.00M |
| EBITDA | -129,000 |
| Operating Margin | -8.53% |
| Return on Equity | -8.98% |
| Return on Assets | -4.82% |
| Revenue/Share (TTM) | $15.60 |
| Book Value | $8.25 |
| Price-to-Book | 3.17 |
| Price-to-Sales (TTM) | 1.80 |
| EV/Revenue | 1.738 |
| EV/EBITDA | 70.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 24.20% |
| Shares Outstanding | $1.79M |
| Float | $1.41M |
| % Insiders | 12.63% |
| % Institutions | 17.71% |
Historical Volatility
HV 10-Day
47.31%
HV 20-Day
66.10%
HV 30-Day
58.79%
HV 60-Day
57.60%
HV Rank
24.6%
Volatility is currently contracting
Latest News
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Zacks Investment Research8/21/2026Positive
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Seeking Alpha8/17/2026Neutral
Precipio Announces Q2-2026 Financial Results
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
GlobeNewsWire8/14/2026Neutral
Precipio Announces Q2-2026 Shareholder Update Call
NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET.
GlobeNewsWire7/31/2026Neutral
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
Zacks Investment Research7/16/2026Positive
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.
GlobeNewsWire6/12/2026Neutral
Precipio to Present at the Planet MicroCap Las Vegas
NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion.
GlobeNewsWire6/11/2026Neutral
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.
Zacks Investment Research5/22/2026Neutral
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Seeking Alpha5/18/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRPO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026